Multiple sclerosis trials recruiting in Wisconsin

All Multiple sclerosis trials nationally

Cities in Wisconsin

Recruiting trials in Wisconsin

• A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
  NCT06587828 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Wisconsin: Milwaukee
• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Wisconsin: Greenfield, Milwaukee, Neenah, Waukesha
• A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
  NCT07067463 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Wisconsin: Milwaukee
• A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
  NCT06680037 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Wisconsin: Milwaukee
• AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
  NCT06063850 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Wisconsin: Milwaukee
• An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
  NCT07224373 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Wisconsin: Milwaukee
• Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
  NCT04047628 · Phase: Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female) · Wisconsin: Milwaukee
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
  NCT06846281 · Phase: Phase 3 · Ages: 40 Years to 70 Years · Sex: All (male and female) · Wisconsin: Greenfield, Milwaukee
• High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis
  NCT05735691 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · Wisconsin: Milwaukee
• RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
  NCT07002034 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Wisconsin: Madison
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
  NCT05877963 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Wisconsin: Milwaukee
• Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
  NCT06408259 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · Wisconsin: Milwaukee
• The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
  NCT06796504 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 60 Years · Sex: All (male and female) · Wisconsin: Milwaukee
• Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
  NCT04806620 · Phase: Not specified · Ages: 2 Years and older · Sex: All (male and female) · Wisconsin: Delafield